Cargando…

Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience

BACKGROUND: The role of immune checkpoint inhibitors (ICIs) in NSCLC patients with EGFR mutations are controversial. In this study, we aim to investigate the therapeutic efficacy of ICIs alone or in combination in patients with EGFR mutated NSCLC in late-line settings, and explore the factors that m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Menglin, Wang, Weiqing, Gao, Xuetian, Wu, Leilei, Jin, Peng, Wu, Hui, Yu, Jinming, Meng, Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918499/ https://www.ncbi.nlm.nih.gov/pubmed/35296087 http://dx.doi.org/10.3389/fimmu.2022.832419

Ejemplares similares

Integrated analysis of EGFR mutated non‐small cell lung cancer reveals two distinct molecular subtypes
por: Bai, Menglin, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
por: Zhou, Shujie, et al.
Publicado: (2022)

Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer
por: Jin, Peng, et al.
Publicado: (2022)

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
por: Wu, Leilei, et al.
Publicado: (2020)

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
por: Ji, Wenxiang, et al.
Publicado: (2022)

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
por: Li, Xiaohua, et al.
Publicado: (2021)

Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
por: Wu, Leilei, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers
por: Lei, Youming, et al.
Publicado: (2022)

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
por: Chen, Qian, et al.
Publicado: (2022)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
por: Wu, Zhen, et al.
Publicado: (2019)

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study
por: Hu, Jia, et al.
Publicado: (2022)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
por: Lin, Anqi, et al.
Publicado: (2019)

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy
por: Lin, Jing, et al.
Publicado: (2022)

Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry
por: Ma, Weijie, et al.
Publicado: (2023)

Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis
por: Hu, Yue, et al.
Publicado: (2023)

Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma
por: Liu, Rongrong, et al.
Publicado: (2022)

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
por: Song, Ruiqiang, et al.
Publicado: (2022)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies
por: Meng, Ying, et al.
Publicado: (2023)

Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Li, Yan, et al.
Publicado: (2021)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
por: Bongiovanni, Alberto, et al.
Publicado: (2021)

Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer
por: Wang, Yao, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
por: Ito, Takashi, et al.
Publicado: (2021)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
por: Chong, Wei, et al.
Publicado: (2020)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
por: Gao, Yuan, et al.
Publicado: (2022)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations
por: Lee, Hyun Woo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4lkq3seima1ic8m1ib2c0u0eb9